This lack of synergy can also be explained by the fact that both therapies activate exclusively mitochondrial apoptosis in SCLC, with strong early caspase-9 and -3 cleavage, and no caspase-8 activation. The gene discussed is CASP8; the disease is small cell lung carcinoma.